Paclitaxel and tamoxifen. An active regimen for patients with metastatic melanoma

Cancer

Volumn 88, Issue 1, 2000, Pages 79-87

  Nathan, Faith E ^a,b   Berd, David ^a   Sato, Takami ^a   Mastrangelo, Michael J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chemotherapy; Melanoma; Paclitaxel; Tamoxifen

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; PACLITAXEL; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MELANOMA; METASTASIS; MYALGIA; NEUROTOXICITY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIODIAGNOSIS; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; PACLITAXEL; SKIN NEOPLASMS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0033970447     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<79::AID-CNCR12>3.0.CO;2-L     Document Type: Article

References (40)

1. Nathan FE, Berd D, Mastrangelo MJ. Chemotherapy of melanoma. In: Perry MC, editor. Chemotherapy source book. 2nd ed. Baltimore: William and Wilkins, 1996:1043-69.
2. Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M. D. Anderson Cancer Center experience. Cancer J Sci Am 1997;3:S9-S15.
3. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-9.
4. Wanit MC, Taylor H, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI: the isolation and structure of Taxol, a novel antileukemia and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
5. Wiernik PH, Einzig AI. Taxol in malignant melanoma. Monogr Natl Cancer Inst 1993;15:185-7.
6. Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P-388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 1984; 44:4392-5.
7. Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC. Modulation of induced resistance to Adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother Pharmacol 1988;22: 147-52.
8. Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B, Andreeff M. Effect of tamoxifen on cell lines displaying the multi-drug-resistance phenotype. Blood 1991;77:818-25.
9. Fine RL, Sachs CW, Albers M, Williams A. Tamoxifen potentiates the cytotoxicity of vinblastine by increasing intracellular drug accumulation [abstract]. Proc Am Assoc Cancer Res 1991;32:375.
10. Kirk J, Houlbrook S, Stuart NSA, Stratford IJ, Harris AL, Carmichael J. Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 1993;67:1189-95.
11. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of Taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-9.
12. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, et al. A Phase I trial of Taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991;9:1261-7.
13. Einzig AI, Wiernik PH, Tenteromano L, et al. Phase I study of Taxol and G-CSF in patients with unresectable malignancy [abstract]. Proc Am Soc Clin Oncol 1994;13:401.
14. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A Phase II trial of Taxol in metastatic melanoma. Cancer 1990; 65:2478-81.
15. Einzig AI, Hochster H, Wiernik PH, et al. A Phase II study of Taxol in patients with malignant melanoma. Invest New Drugs 1991;9:59-64.
16. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of Taxol in patients with advanced cancer. Cancer Treat Rep 1987;71:1171-7.
17. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JK, Tormey DC, et al. Phase I study of Taxol administered as a short IV infusion daily for 5 days. Cancer Treat Rep 1987;71: 1179-84.
18. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
19. Mamounas E, Brown A, Smith R, et al. Effect of Taxol duration of infusion in advanced breast cancer (abc): results from NSABP B-26 trial comparing 3-to 24-hr infusion of high-dose Taxol [abstract]. Proc Am Soc Clin Oncol 1998;17: 101a.
20. Breier S, Lebedinsky C, Pelayes L, et al. Preliminary analysis, weekly paclitaxel (P) in previously treated patients (pts) with metastatic disease [abstract]. Proc Am Soc Clin Oncol 1996; 15:182.
21. Fennelly D, Shapiro F, Aghajanian C, et al. Dose-intensive paclitaxel (ptx) delivery utilizing a weekly (w) one-hour (h) infusion schedule: efficacy and feasibility in patients (pts) with persistent ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:286.
22. Alvarez A, Mickiewicz E, Piris B, et al. Weekly Taxol high dose intensity (DI) treatment. Phase II study [abstract]. Proc Am Soc Clin Oncol 1996;15:183.
23. Briasoulis E, Tzamakou E, Nicolaides C, Karavasilis V, Pavlidis N. Long-term weekly (wk) administration of paclitaxel (ptx) in chemotherapy naive patients, Phase I study: single versus cumulative dose limiting toxicity (sDLT/CDLT) [abstract] Proc Am Soc Clin Oncol 1997;16:231a.
24. Alvarez A, Mickiewicz E, Brosio C, et al. Weekly Taxol (T) in patients who had relapsed or remained stable with T in a 21 day schedule [abstract]. Proc Am Soc Clin Oncol 1998;17: 188a.
25. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, Le Marbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984;68:1403-5.
26. McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987;71:465-9.
27. McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989;63:1292-5.
28. DeGregorio MW, Ford JM, Benz EC, Wiebe WJ. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 1989;7:1359-64.
29. Fabian C, Sternson L, Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 1980;64:765-73.
30. Mastrangelo MJ. Controlled studies in chemotherapy for advanced melanoma. In: Lejeune FJ, Chaudhuri PK, Das Gupta TK, editors. Malignant melanoma: medical and surgical management. New York: McGraw-Hill, Inc., 1994:295-301.
31. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, et al. Characterization of a human myeloid leukemia cell line highly resistant to Taxol. Leukemia 1994;8:465-75.
32. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP, et al. Taxol: mechanisms of action and resistance. Monogr Natl Cancer Inst 1993;15:55-61.
33. De Vincenzo R, Scambia G, Panici PB, Fattorossi A, Bonanno G, Ferlini C, et al. Modulatory effect of tamoxifen and ICI 182,789 on Adriamycin resistance in MCF human breast-cancer cells. Int J Cancer 1996;68:340-8.
34. Berman E, McBride M, Lin S, Menedez-Botet C, Tong W. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 1995; 9:1631-7.
35. Desai PB, Bhardwaj R, Damle B. Effect of tamoxifen on mitoxantrone cytotoxicity in drug-sensitive and multidrug-resistant MCF-7 cells. Cancer Chemother Pharmacol 1995; 36:368-72.
36. Cantwell B, Carmichael J, Millward M, Chatterjee M, Harris AL. Intermittent high dose tamoxifen (HDT) with oral etoposide (EPO): Phase I and II clinical studies. Proc Am Soc Clin Oncol 1989;8:65.
37. Ferlini C, Scambi G, Distefano M, Filippini P, Isola G, Riva A, et al. Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br J Cancer 1997;75:884-91.
38. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, et al. High-dose oral tamoxifen, a potential multi-drug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 1992;84:1811-6.
39. Millward MJ, Cantwell BMJ, Lien EA, Carmichael J, Harris A. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992;28A:805-10.
40. Kaye SB. Reversal of multidrug resistance. Cancer Treat Rev 1990;17:37-43.